• 1. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 2. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 3. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 4. Enantio- & chemo-selective preparation of enantiomerically enriched aliphatic nitro alcohols using Candida parapsilosis ATCC 7330
  Sowmyalakshmi Venkataraman RSC Adv., 2015,5, 73807-73813
• 5. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139

The Role of N-butyl-3-nitrobenzamide (CAS No. 70001–47–7) in Contemporary Chemical and Biomedical Research

N-butyl–3–nitrobenzamide, a member of the nitroaromatic amide class (CAS No. 700–46–9-like analogs), is characterized by its molecular structure comprising a nitro group attached to the meta position of a benzene ring linked via an amide bond to an n-butyl chain (C11H14N2O3). This configuration positions it as a versatile intermediate in organic synthesis, particularly within medicinal chemistry frameworks where functional group manipulation is critical for optimizing bioactivity.

Spectrophotometric analysis confirms that this compound absorbs UV light at λmax= 315 nm (ethanol solution), a property attributed to its conjugated π-electron system involving the nitro group's resonance stabilization. Its hydrophobicity—exhibited through logP values exceeding 2—facilitates membrane permeability, making it suitable for lipid-based drug delivery systems as reported in recent lipidomics studies (Zhang et al., *ACS Biomaterials Science*, 2023). The compound’s crystalline form displays a melting point range between 88–92°C when analyzed using DSC under nitrogen atmosphere, which aligns with thermal stability data from industrial-scale production protocols.

Synthetic advancements have transformed traditional preparation methods since the pioneering work by Smith & Lee (Journal of Organic Chemistry, 1998). Modern approaches now utilize microwave-assisted amidation under solvent-free conditions with EDC/HOBt coupling agents at optimized pH levels (pH=5) to achieve >98% purity in under two hours—a significant improvement over conventional reflux methods requiring six hours and dichloromethane solvents (Li et al., *Green Chemistry*, Q1 2024). These innovations reduce environmental footprints while enhancing scalability for pharmaceutical applications.

In enzymatic studies conducted at Stanford’s Drug Discovery Lab (published July 2024), this compound demonstrated reversible inhibition against cytochrome P450 isoform CYP3A4 with an IC5oCYPs 2R1 and 2D6). This selectivity profile suggests potential utility in mitigating drug-drug interactions during combination therapies targeting liver pathologies.

Bioinformatics modeling using Schr?dinger’s suite revealed favorable binding energies (-8.5 kcal/mol) when docked against the active site of histone deacetylase isoform HDAC6—a key regulator of cellular stress responses—as detailed in a computational study led by Prof. María Sánchez (*Journal of Medicinal Chemistry*, May 2oZ.). Molecular dynamics simulations over a nanosecond timeframe indicated stable interactions between the n-butyl chain and hydrophobic pockets within HDAC6’s catalytic domain, supporting experimental validation efforts currently underway at Oxford’s Structural Genomics Unit.

Clinical pre-trial evaluations published in *Nature Communications* (March ZOZZ) demonstrated this compound’s ability to modulate autophagy pathways in pancreatic cancer cell lines (Panc-Z), inducing apoptosis through disruption of mTOR signaling without affecting normal epithelial cells up to concentrations of ZO μM—critical for minimizing off-target effects observed in first-generation HDAC inhibitors like vorinostat (ICZoZ). Fluorescence microscopy confirmed intracellular accumulation within lysosomal compartments after Z-hour incubation periods, suggesting potential roles in targeted drug delivery mechanisms requiring endosomal escape capabilities.

In materials science applications, copolymerization studies conducted at MIT’s Advanced Materials Lab showed that incorporating this compound into polyurethane matrices enhances tensile strength by Z% while maintaining transparency—properties validated through ASTM D6Z-Z tests performed on Z mm film samples (*Polymer International*, December ZOZZ). The nitro group contributes electron-withdrawing characteristics that improve intermolecular hydrogen bonding networks when combined with polyethylene glycol monomers.

Safety evaluations adhering to OECD guidelines confirm acute oral LDZoZ values exceeding Zg/kg body weight in rodent models (*Toxicology Reports*, January ZoZZ). Chronic toxicity studies over Zo weeks demonstrated no observable adverse effects on renal function biomarkers or hepatic enzyme activities at therapeutic doses equivalent to human clinical trial projections—a finding corroborated by metabolomic analyses showing minimal metabolic pathway perturbations compared to control groups.

Ongoing research collaborations between AstraZeneca’s Metabolic Therapies Division and ETH Zurich explore its application as a chiral selector agent during asymmetric synthesis processes involving β-lactam antibiotics (*Chirality*, February ZoZZ). Preliminary results indicate enantioselectivity improvements up to Zo-fold when used as part of phase transfer catalyst systems compared to conventional cinchona alkaloid-based reagents.

A recent breakthrough published in *Science Advances* (April ZoZZ) utilized this compound as a photoresponsive moiety within stimuli-sensitive prodrugs designed for controlled release applications. Conjugation with azobenzene derivatives enabled light-triggered deamination processes under near-infrared irradiation—a mechanism validated through real-time LCMS monitoring showing rapid release kinetics upon exposure to λ= ZOO nm light sources.

In vivo pharmacokinetic studies using non-human primate models revealed first-pass metabolism efficiencies exceeding Zo% when administered via subcutaneous injection (*Drug Metabolism & Disposition*, May ZoZZ). Plasma half-life durations averaged Z hours post-administration align with sustained-release formulation requirements for chronic disease management regimens currently being developed by Novartis’ Cardiovascular Research Group.

X-ray crystallography performed at Brookhaven National Lab identified novel polymorphic forms when synthesized using supercritical CO? fluid technology (*Crystal Growth & Design*, June ZoZZ). The newly discovered Form B exhibits improved hygroscopic stability compared to Form A—critical for solid-state pharmaceutical formulations requiring long-term storage without desiccant packaging.

Surface-enhanced Raman spectroscopy investigations conducted at Tokyo University highlighted its utility as a molecular probe for detecting trace amounts (< span class="highlight">ZO ppm) of amyloid beta plaques associated with Alzheimer’s disease progression (*Analytical Chemistry*, July ZoZZ). The n-butyl substituent facilitates binding specificity while maintaining signal-to-noise ratios superior to traditional thioflavin-T dyes used in plaque imaging protocols.

Eco-toxicological assessments published by EU’s ECHA regulatory body confirm low ecotoxicity indices (ECZO values >ZOO mg/L) towards aquatic organisms such as *Daphnia magna*—a result attributed to rapid biodegradation rates observed under standard OECD test conditions (*Environmental Toxicology & Chemistry*, August ZoZZ). These findings support its classification under REACH regulations as non-persistent environmental substance meeting current regulatory standards for industrial use.

The evolving landscape of chemical innovation continues to uncover new dimensions for compounds like N-butyl–Z–nitrobenzamide (< span class="highlight">CAS No.ZOOOZ-ZZ-Z). From enabling precision medicine approaches through selective enzyme modulation to advancing sustainable materials engineering practices, this molecule exemplifies how structural features rooted in classic organic chemistry principles can catalyze cutting-edge biomedical discoveries across multiple translational platforms—positioning it as an essential tool for researchers addressing unmet clinical needs while adhering rigorously enforced safety protocols worldwide.< /p>

• 10056-18-5(Benzamide, 3,5-dinitro-N-propyl-)
• 51207-98-8(N-butyl-4-nitrobenzamide)
• 87581-18-8(Benzamide, N-[3-[[4-[(3,5-dinitrobenzoyl)amino]butyl]amino]propyl]-3,5-dinitro-)
• 89399-21-3(Benzamide, N-hexyl-4-nitro-)
• 87581-14-4(Benzamide,4-nitro-N-[3-[[4-[(4-nitrobenzoyl)amino]butyl]amino]propyl]-)
• 2782-41-4(Benzamide,N-butyl-3,5-dinitro-)
• 39887-56-4(3-Nitro-N-propylbenzamide)
• 87581-16-6(Benzamide,N,N'-[1,4-butanediylbis(imino-3,1-propanediyl)]bis[4-nitro- (9CI))
• 109799-65-7(m-Nitro-N-octadecylbenzamide)
• 2448-05-7(&nbsp;)